Back to previous page


Name: Abivax
Market: Euronext Paris
Capitalization compartment: Compartment C
Subsector: Biotechnology
Isin code: FR0012333284
Symbol: ABVX


IPO Date: 26/06/2015
Issue type: Initial Public offering
Price range: EUR 18.26 - EUR 24.34

Company Profile

Loading... Please wait.


Date Title
26 Jun 2015 Abivax lists on Euronext Paris expand

Raises €57.7 million, market capitalisation €205 million

Paris – 26 June 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1], todaycelebrated the listing of Abivax, a biotech company specialising in the clinical development and commercialisation of anti-viral therapies. Abivax listed in Compartment B of Euronext Paris.

Abivax is a biotech company that aims to become a leader in the discovery, development and commercialisation of new anti-viral compounds. It focuses on some of the world’s most severe or life-threatening infectious diseases including chronic Hepatitis B, HIV/AIDS, Ebola, Dengue fever and Chikungunya. Abivax is based in France with operations in Paris, Évry and Montpellier, and does pioneering work with biotechnology institutes in Cuba , the CNRS in Montpellier, the Institute Pasteur and the Institute Curie in Paris as well as the Scipps Research Institute in Lo Jolla, California.

Abivax (ticker code: ABVX) was listed through the admission to trading of the 9,624,889 shares making up its equity, including 2,707,089 new shares issued under a Global Offering[2], after the full exercise of the extension option and over-allotment option.

The admission and issue price of Abivax shares was set at €21.30 per share. Market capitalisation was    205 million on the day of listing, and the transaction raised a total of  57.7 million.

Prof Hartmut Ehrlich, CEO of Abivax said:“We are proud to join the biotechnology companies listed on Euronext in Paris, with strong demand from institutional investors and, European family offices that showed their support very early on in our listing process, as well as retail investors.”

Dr Philippe Pouletty, founder and chairman of Abivax added:“Abivax will be able to pursue its leading strategy in immuno-virology with the development for commercialisation of its new anti-viral compounds, notably for patients suffering from chronic Hepatitis B, AIDS, Dengue fever and Chikungunya, building on the work of our research centre in Montpellier and our close ties with biotechnology institutions in Cuba and with France’s CNRS.”

Eric Forest, CEO of EnterNext, said: “We extend a warm welcome to Abivax as it lists on Euronext. Abivax is the ninth life sciences specialist to join our markets since the beginning of the year. In doing so, it becomes part of a community of over 70 listed biotech and medtech companies, the largest in Europe. Listing will enable Abivax to pursue its clinical development programme and prepare for the commercialisation of its new compounds. We are convinced that listing will serve the group’s growth strategy.”

[1]Small and medium-size companies
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries


26 Jun 2015 Abivax expand

EnterNext welcomes Abivax on Euronext in Paris

Professor Hartmut Ehrlich, CEO of Abivax, rings the closing bell.

Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases.
At the end of 2014, the Group has a portfolio of three products in clinical development: ABX203 (therapeutic vaccine against chronic hepatitis B), ABX464 (new drug against HIV) and ABX196 (adjuvant vaccine against hepatitis B).